farnesylacetamide | 148162-65-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: farnesylacetamide
• 英文别名: N-farnesylacetamide；N-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)acetamide；N-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]acetamide
• CAS: 148162-65-6
• 化学式: C₁₇H₂₉NO
• 分子量: 263.423
• InChiKey: ZTIOVNSRRZYQRZ-NCZFFCEISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  19
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  farnesylacetamide 在 lithium aluminium tetrahydride 作用下， 以 乙醚 为溶剂， 反应 16.0h， 以55%的产率得到N-ethylfarnesylamine
  参考文献：
  名称：

  N-（芳基烷基）法呢基胺：新型强力角鲨烯合成酶抑制剂。

  摘要：

  DOI：

  10.1021/jm00062a026
• 作为产物：
  描述：

  乙酰胺 、 反,反-法呢基溴 在 四丁基溴化铵 、 sodium hydride 作用下， 生成 farnesylacetamide
  参考文献：
  名称：

  A Convenient Preparation of Farnesylamine

  摘要：

  The efficient synthesis of farnesylamine (1) was accomplished by two separate routes. The first, by the alkylation of triflouroacetamide with farnesyl bromide followed by base hydrolysis. The second, by displacement of the halogen of farnesyl bromide with lithium bis(trimethylsilyl)amide followed by methanolysis.

  DOI：

  10.1080/00397919308009810

文献信息

• Screening for Small Molecule Modulators of Trypanosoma brucei Hsp70 Chaperone Activity Based upon Alcyonarian Coral-Derived Natural Products
  作者：Sarah K. Andreassend、Stephen J. Bentley、Gregory L. Blatch、Aileen Boshoff、Robert A. Keyzers

  DOI：10.3390/md18020081

  日期：——

  The Trypanosoma brucei Hsp70/J-protein machinery plays an essential role in survival, differentiation, and pathogenesis of the protozoan parasite, and is an emerging target against African Trypanosomiasis. This study evaluated a set of small molecules, inspired by the malonganenones and nuttingins, as modulators of the chaperone activity of the cytosolic heat inducible T. brucei Hsp70 and constitutive TbHsp70.4 proteins. The compounds were assessed for cytotoxicity on both the bloodstream form of T. b. brucei parasites and a mammalian cell line. The compounds were then investigated for their modulatory effect on the aggregation suppression and ATPase activities of the TbHsp70 proteins. A structure–activity relationship for the malonganenone-class of alkaloids is proposed based upon these results.

  Trypanosoma brucei的Hsp70/J-蛋白质机制在原虫寄生虫的生存、分化和致病过程中发挥着关键作用，是针对非洲锥虫病的新兴靶点。该研究评估了一组受malonganenones和nuttingins启发的小分子，作为调节细胞质热诱导T. brucei Hsp70和TbHsp70.4蛋白质的分子伴侣活性的调节剂。这些化合物对T. b. brucei寄生虫的血流形式和哺乳动物细胞系的细胞毒性进行了评估。然后，研究了这些化合物对TbHsp70蛋白的聚集抑制和ATP酶活性的调节作用。根据这些结果，提出了malonganenone类生物碱的结构-活性关系。
• FARNESYLAMINE DERIVATIVES AND METHODS OF USE
  申请人：Kothapalli Ravi

  公开号：US20100227811A1

  公开（公告）日：2010-09-09

  The present invention concerns farnesylamine derivatives, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of ras-mediated signal transduction and inhibitors of aberrant cell growth, e.g., as anti-cancer agents, as well as anti-fungal agents. Other non-malignant diseases characterized by proliferation of cells that may be treated using the farneylamine derivatives of the include, but are not limited to, cirrhosis of the liver; graft rejection; restenosis; and disorders characterized by a proliferation of T cells such as autoimmune diseases, e.g., type 1 diabetes, lupus and multiple sclerosis.

  本发明涉及法尼酰胺衍生物、含有这些化合物的组合物以及将这些化合物和组合物用作抑制ras介导的信号传导和异常细胞生长的抑制剂，例如作为抗癌剂以及抗真菌剂的方法。其他非恶性疾病，其特征是细胞增殖可能使用所述法尼酰胺衍生物进行治疗，但不限于肝硬化；移植排斥反应；再狭窄；以及以T细胞增殖为特征的疾病，例如自身免疫性疾病，例如1型糖尿病，狼疮和多发性硬化症。
• Geranylgeranylacetamide compounds having a piperazine ring, salts thereof, process for preparation thereof, pharmaceutical compositions containing said compounds, and method of treating ulcers in mammals
  申请人：Nihon Iyakuhin Kogyo Co., Ltd.

  公开号：EP0096393A1

  公开（公告）日：1983-12-21

  A geranylgeranylacetamide compound having a piperazine ring represented by the following formula (1) wherein R represents a member selected from the class consisting of a hydrogen atom, C1-C5 alkyl groups which are unsubstituted or mono-substituted by a halogen atom, C2-C5 alkenyl groups and C7-C8 aralkyl groups, R, represents a C1-C3 alkyl group, and n represents 0, 1 or 2, and a pharmaceutically acceptable acid addition salt thereof. The aforesaid compound can be prepared by reacting geranylgeranylacetic acid or its reactive derivative with a piperazine compound, and therafter, if desired, transforming the free geranylgeranylacetamide compound thus obtained into its pharmaceutically acceptable acid addition salt. A phamaceu- tical composition containing said compound exhibits anti- ulcerogenic activity, particularly excellent antipeptic ulcerogenic activity, and is useful an agent for treating ulcers.

  一种具有下式（1）所代表的哌嗪环的香叶基乙酰胺化合物 其中 R 代表选自氢原子、未被卤素原子取代或被卤素原子单取代的 C1-C5 烷基、C2-C5 烯基和 C7-C8 芳基所组成的类别中的一个成员，R 代表 C1-C3 烷基，n 代表 0、1 或 2，以及其药学上可接受的酸加成盐。上述化合物可通过香叶基乙酸或其活性衍生物与哌嗪化合物反应制备，然后，如果需要，将由此获得的游离香叶基乙酰胺化合物转化为其药学上可接受的酸加成盐。含有上述化合物的医药组合物具有抗溃疡活性，尤其是优异的抗消化性溃疡活性，是治疗溃疡的有效药物。
• Drug carriers
  申请人：NIPPON SHINYAKU COMPANY, LIMITED

  公开号：EP0315079A1

  公开（公告）日：1989-05-10

  A drug carrier in the form of a fat emulsion, which contains a drug and has a mean particle diameter of less than 200 nm.

  脂肪乳液形式的药物载体，含有药物，平均颗粒直径小于 200 纳米。
• LYOPHILIZED PREPARATION AND PRODUCTION THEREOF
  申请人：NIPPON SHINYAKU COMPANY, LIMITED

  公开号：EP0556394A1

  公开（公告）日：1993-08-25

  A lyophilized preparation which releases a fat emulsion, wherein the emulsion particle has a mean diameter of 10 to 100 nm, when redissolved prior to use. This preparation is produced by adding maltose in an arbitrary stage of the production of said emulsion prior to lyophilization.

  一种冻干制剂，使用前重新溶解时可释放出脂肪乳液，其中乳液颗粒的平均直径为 10 至 100 纳米。这种制剂是在冻干前生产所述乳液的任意阶段加入麦芽糖制成的。